Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.

Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S.

Support Care Cancer. 2016 Jul;24(7):3085-93. doi: 10.1007/s00520-016-3119-0. Epub 2016 Feb 19.

PMID:
26894485
2.

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.

Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE.

J Thromb Haemost. 2015 Jun;13(6):998-1003. doi: 10.1111/jth.12910. Epub 2015 Apr 23.

PMID:
25809746
3.

Delayed human herpes virus 6 encephalitis in a patient with allogeneic stem cell transplant.

O'Toole J, Ades S, Waters BL, Agarwal Z, Lamba G.

Leuk Lymphoma. 2015;56(9):2709-10. doi: 10.3109/10428194.2014.1003054. Epub 2015 Feb 11. No abstract available.

PMID:
25629987
4.

Identification of inhibitors of a bacterial sigma factor using a new high-throughput screening assay.

El-Mowafi SA, Sineva E, Alumasa JN, Nicoloff H, Tomsho JW, Ades SE, Keiler KC.

Antimicrob Agents Chemother. 2015 Jan;59(1):193-205. doi: 10.1128/AAC.03979-14. Epub 2014 Oct 20.

5.

Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Sudarshan M, Alcindor T, Ades S, Aloraini A, van Huyse M, Asselah J, David M, Frechette D, Brisson S, Thirlwell M, Ferri L.

Ann Surg Oncol. 2015 Jan;22(1):324-30. doi: 10.1245/s10434-014-3875-3. Epub 2014 Jul 15.

PMID:
25023544
6.

Cell-based assay to identify inhibitors of the Hfq-sRNA regulatory pathway.

El-Mowafi SA, Alumasa JN, Ades SE, Keiler KC.

Antimicrob Agents Chemother. 2014 Sep;58(9):5500-9. doi: 10.1128/AAC.03311-14. Epub 2014 Jul 7.

7.
8.

Absence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract.

Miller J, Peng Z, Wilcox R, Evans M, Ades S, Verschraegen C.

Gastrointest Cancer Res. 2014 Mar;7(2):39-41.

9.

Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.

Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, Ades S, Burke GL, Cushman M.

J Thromb Haemost. 2013 Jun;11(6):1078-84. doi: 10.1111/jth.12223.

10.

Regulated proteolysis: control of the Escherichia coli σ(E)-dependent cell envelope stress response.

Barchinger SE, Ades SE.

Subcell Biochem. 2013;66:129-60. doi: 10.1007/978-94-007-5940-4_6. Review.

PMID:
23479440
11.

Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.

Alcindor T, Ferri LE, Marcus V, Andalib A, Hickeson M, Artho G, Chasen M, Thirlwell MP, Ades S.

Med Oncol. 2013 Mar;30(1):377. doi: 10.1007/s12032-012-0377-7. Epub 2012 Dec 29.

PMID:
23275118
12.

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group.

Eur Urol. 2013 Dec;64(6):994-1002. doi: 10.1016/j.eururo.2012.11.032. Epub 2012 Nov 21.

PMID:
23219086
13.

In-advance end-of-life discussions and the quality of inpatient end-of-life care: a pilot study in bereaved primary caregivers of advanced cancer patients.

Mori M, Ellison D, Ashikaga T, McVeigh U, Ramsay A, Ades S.

Support Care Cancer. 2013 Feb;21(2):629-36. doi: 10.1007/s00520-012-1581-x. Epub 2012 Aug 30.

PMID:
22933133
14.

sigE facilitates the adaptation of Bordetella bronchiseptica to stress conditions and lethal infection in immunocompromised mice.

Barchinger SE, Zhang X, Hester SE, Rodriguez ME, Harvill ET, Ades SE.

BMC Microbiol. 2012 Aug 16;12:179. doi: 10.1186/1471-2180-12-179.

15.

Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.

Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP.

Ann Oncol. 2012 Jun;23(6):1512-7. doi: 10.1093/annonc/mdr465. Epub 2011 Oct 29.

16.

Physiological response to membrane protein overexpression in E. coli.

Gubellini F, Verdon G, Karpowich NK, Luff JD, Boël G, Gauthier N, Handelman SK, Ades SE, Hunt JF.

Mol Cell Proteomics. 2011 Oct;10(10):M111.007930. doi: 10.1074/mcp.M111.007930. Epub 2011 Jun 30.

17.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group.

Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219.

18.

Promoter strength properties of the complete sigma E regulon of Escherichia coli and Salmonella enterica.

Mutalik VK, Nonaka G, Ades SE, Rhodius VA, Gross CA.

J Bacteriol. 2009 Dec;191(23):7279-87. doi: 10.1128/JB.01047-09. Epub 2009 Sep 25.

19.

Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice.

Ades S.

Oncology (Williston Park). 2009 Feb;23(2):162-7. Review.

20.

Regulation by destruction: design of the sigmaE envelope stress response.

Ades SE.

Curr Opin Microbiol. 2008 Dec;11(6):535-40. doi: 10.1016/j.mib.2008.10.004. Epub 2008 Nov 7. Review.

PMID:
18983936
Items per page

Supplemental Content

Loading ...
Write to the Help Desk